Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 17 Researches
7.6
USERS' SCORE
Good
Based on 2 Reviews
8.6
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin C (as Ascorbyl palmitate)
10 mg
11%
Vitamin K activity
2600 mcg
2167%
Vitamin K1 (as phytonadione)
1500 mcg
Vitamin K2 (as menaquinone-4)
1000 mcg
Vitamin K2 (as trans menaquinone-7)
100 mcg
Top Medical Research Studies
9
We aimed to discover how well PIVKA-II can predict treatment response in patients with non-AFP-secreting hepatocellular carcinoma (HCC) receiving systemic therapy.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
Read More
8
We explored how a vitamin K precursor, known as menadione sodium bisulfite (MSB), influences prostate cancer progression in mice. Contrary to concerns surrounding antioxidants like vitamin E, our findings suggest that MSB acts as a pro-oxidant, successfully reducing cancer cell growth via oxidative cell death.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
Read More
8
We investigated how vitamin K2 (VK2) influences the growth of cancer cells, particularly focusing on hepatocellular carcinoma (HCC). Our study centered on the interaction between VK2 and a protein known as HSD17B4, which is known to promote cancer cell proliferation. Previous research had shown that VK2 can bind to this protein, but we aimed to uncover the specific mechanisms behind its potential anti-cancer effects.
Through our experiments, we observed that VK2 can inhibit the growth of HCC cells by binding directly to HSD17B4. Interestingly, VK2 did not alter the expression levels of HSD17B4, which suggests that its impact on cell growth is due to other mechanisms. Specifically, we found that VK2 impedes the activation of important signaling pathways, including AKT and MEK/ERK, which play a critical role in cancer cell proliferation. As a result, this inhibition leads to decreased activity of another protein, STAT3, associated with cancer growth.
Moreover, VK2 demonstrated the ability to suppress the growth of transplanted tumors that were influenced by HSD17B4. These findings not only shed light on VK2's mechanism of action, but they also offer promising insights into its potential role in preventing or treating HCC in future applications.
Through our experiments, we observed that VK2 can inhibit the growth of HCC cells by binding directly to HSD17B4. Interestingly, VK2 did not alter the expression levels of HSD17B4, which suggests that its impact on cell growth is due to other mechanisms. Specifically, we found that VK2 impedes the activation of important signaling pathways, including AKT and MEK/ERK, which play a critical role in cancer cell proliferation. As a result, this inhibition leads to decreased activity of another protein, STAT3, associated with cancer growth.
Moreover, VK2 demonstrated the ability to suppress the growth of transplanted tumors that were influenced by HSD17B4. These findings not only shed light on VK2's mechanism of action, but they also offer promising insights into its potential role in preventing or treating HCC in future applications.
Read More
Most Useful Reviews
8.8
Fighting cancer risks
A crucial nutrient, Vitamin K2 is often lacking in our diets. Life Extension is a reputable brand. K2 helps ensure calcium is deposited in bones rather than soft tissues, crucial for people with hepatic cancers, as it can significantly decrease mortality rates. It’s best to take K with vitamin D for maximum efficacy. Overall, K2 is important for health and may aid in reducing cancer risk.
Read More
8.8
Potential cancer fighter
Seems like a good product. I regularly take Life Extension K2 and appreciate its importance for bone and arterial health. While it's hard to feel direct effects from supplements, K2 has a lot of supportive research. It helps keep calcium in bones rather than arteries and may assist in fighting cancer. The MK-7 form is natural and suggests better absorption. I've chosen this brand due to its quality and cost-effectiveness; it fits well into a healthy lifestyle.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 17 Researches
7.6
- All Researches
9.5
We observed how vitamin K2 (VK2) could play a significant role in enhancing the effectiveness of a common treatment for acute myeloid leukemia (AML) called venetoclax (VEN). In our investigation, older patients diagnosed with AML showed promising responses to a treatment combination of VEN and another drug, azacitidine (AZA), alongside daily VK2 intake. Remarkably, we noted a complete response rate of about 79% among patients taking VK2, highlighting the potential of VK2 to improve treatment outcomes.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Read More
9
We aimed to discover how well PIVKA-II can predict treatment response in patients with non-AFP-secreting hepatocellular carcinoma (HCC) receiving systemic therapy.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
Read More
8
EZJDD improves liver cancer outcomes
We evaluated the effectiveness and safety of Erzhu Jiedu Decoction (EZJDD) Granules in patients with mid-advanced liver cancer linked to hepatitis B.
In a study involving 132 patients, we randomly assigned them into two groups—one receiving standard treatment and the other receiving standard treatment along with EZJDD Granules for three months.
The results showed that EZJDD significantly extended progression-free survival and boosted the six-month survival rate, suggesting it may enhance treatment outcomes for this challenging condition.
In a study involving 132 patients, we randomly assigned them into two groups—one receiving standard treatment and the other receiving standard treatment along with EZJDD Granules for three months.
The results showed that EZJDD significantly extended progression-free survival and boosted the six-month survival rate, suggesting it may enhance treatment outcomes for this challenging condition.
Read More
8
We explored how a vitamin K precursor, known as menadione sodium bisulfite (MSB), influences prostate cancer progression in mice. Contrary to concerns surrounding antioxidants like vitamin E, our findings suggest that MSB acts as a pro-oxidant, successfully reducing cancer cell growth via oxidative cell death.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
Read More
8
We examined the connection between fat-soluble vitamins, specifically vitamin K, and the progression of gliomas, which are particularly aggressive brain cancers. Using The Cancer Genome Atlas database, we found that vitamin K-related metabolic processes are closely linked with the severity and poor prognosis of gliomas.
Notably, a key gene, VKORC1, which is vital for vitamin K's function, showed a strong association with glioma aggressiveness. In laboratory settings, silencing this gene reduced glioma cell growth and movement. Although the results are promising, clinical effects in patients remain to be conclusively determined.
Notably, a key gene, VKORC1, which is vital for vitamin K's function, showed a strong association with glioma aggressiveness. In laboratory settings, silencing this gene reduced glioma cell growth and movement. Although the results are promising, clinical effects in patients remain to be conclusively determined.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Fighting cancer risks
A crucial nutrient, Vitamin K2 is often lacking in our diets. Life Extension is a reputable brand. K2 helps ensure calcium is deposited in bones rather than soft tissues, crucial for people with hepatic cancers, as it can significantly decrease mortality rates. It’s best to take K with vitamin D for maximum efficacy. Overall, K2 is important for health and may aid in reducing cancer risk.
Read More
8.8
Potential cancer fighter
Seems like a good product. I regularly take Life Extension K2 and appreciate its importance for bone and arterial health. While it's hard to feel direct effects from supplements, K2 has a lot of supportive research. It helps keep calcium in bones rather than arteries and may assist in fighting cancer. The MK-7 form is natural and suggests better absorption. I've chosen this brand due to its quality and cost-effectiveness; it fits well into a healthy lifestyle.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Bauer T, Richter-Eder S, Yasmin N, Jurkin J, Köffel R, et al. Vitamin K supports TGF-β1 depended human Langerhans cell differentiation and function via Axl. Front Immunol. 2025;16:1509228. doi:10.3389/fimmu.2025.1509228
- Chen SC, Ho HL, Liu CA, Hung YP, Chiang NJ, et al. PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma. BMC Cancer. 2025;25:199. doi:10.1186/s12885-025-13568-4
- Kaneyasu Y, Fujiwara H, Akita T, Tanaka J, Shibata Y, et al. Suppressive effect of vitamin K (menatetrenone) against bone mineral density loss after radiotherapy in uterine cancer patients. Jpn J Radiol. 2025. doi:10.1007/s11604-025-01733-5
- Cheng Y, Wang HY, Wan CY, Shi JW, Jin YY, et al. Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome. Chin J Integr Med. 2024. doi:10.1007/s11655-024-3818-1
- Swamynathan MM, Kuang S, Watrud KE, Doherty MR, Gineste C, et al. Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function. Science. 2024;386:eadk9167. doi:10.1126/science.adk9167
- Sasaki Y, Tokumura K, Yoshimoto M, Hinoi E. Association between Fat-Soluble Vitamin Metabolic Process and Glioma Progression. Biol Pharm Bull. 2024;47:1682. doi:10.1248/bpb.b24-00275
- Kaneyasu Y, Fujiwara H, Akita T, Tanaka J, Shibata Y, et al. Suppressive effect of vitamin K (menatetrenone) against bone mineral density loss after radiotherapy in uterine cancer patients. Jpn J Radiol. 2025. doi:10.1007/s11604-025-01733-5
- Okabe S, Arai Y, Gotoh A. Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity. Int J Mol Sci. 2024;25. doi:10.3390/ijms252111800
- Tauchi T, Moriya S, Okabe S, Kazama H, Miyazawa K, et al. Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. PLoS One. 2024;19:e0307662. doi:10.1371/journal.pone.0307662
- Okabe S, Gotoh A. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells. BMC Cancer. 2023;23:827. doi:10.1186/s12885-023-11304-4
- Narvaez CJ, Bak MJ, Salman N, Welsh J. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)D in triple negative breast cancer cells. J Steroid Biochem Mol Biol. 2023;231:106307. doi:10.1016/j.jsbmb.2023.106307
- Jadhav N, Ajgaonkar S, Saha P, Gurav P, Pandey A, et al. Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities. Front Pharmacol. 2022;13:896920. doi:10.3389/fphar.2022.896920
- Lu X, Ma P, Kong L, Wang X, Wang Y, et al. Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4. Front Oncol. 2021;11:757603. doi:10.3389/fonc.2021.757603
- Solmaz I, Ozdemir MA, Unal E, Abdurrezzak U, Muhtaroglu S, et al. Effect of vitamin K2 and vitamin D3 on bone mineral density in children with acute lymphoblastic leukemia: a prospective cohort study. J Pediatr Endocrinol Metab. 2021;34:441. doi:10.1515/jpem-2020-0637
- Haruna Y, Yakushijin T, Kawamoto S. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study. Cancer Med. 2021;10:914. doi:10.1002/cam4.3674
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, et al. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021;40:3370. doi:10.1016/j.clnu.2020.11.009
- Daisley BA, Chanyi RM, Abdur-Rashid K, Al KF, Gibbons S, et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 2020;11:4822. doi:10.1038/s41467-020-18649-5
